Mechanism of action of 5-aminosalicylic acid and its derivatives
- PMID: 2155736
- DOI: 10.1042/cs0780119
Mechanism of action of 5-aminosalicylic acid and its derivatives
Abstract
The mechanism of action of 5-ASA and its derivatives remains obscure. The most likely mechanisms would appear to be an interrelationship between local production of eicosanoids and reactive oxygen metabolites, in conjunction with activated neutrophils, though the nature of the initial triggering factor/s remains to be determined. The possibility that bacterial-derived chemotactic peptides, such as FMLP, might be a triggering factor is an attractive possibility, made possible by an underlying defect in mucosal permeability.
Similar articles
-
Antioxidant properties of 5-aminosalicylic acid: potential mechanism for its protective effect in ulcerative colitis.Adv Exp Med Biol. 1995;371B:1317-21. Adv Exp Med Biol. 1995. PMID: 7502808 Review. No abstract available.
-
Effects of BX661A, a new therapeutic agent for ulcerative colitis, on chemotaxis and reactive oxygen species production in polymorphonuclear leukocytes in comparison with salazosulfapyridine and its metabolite sulfapyridine.Arzneimittelforschung. 1998 Dec;48(12):1163-7. Arzneimittelforschung. 1998. PMID: 9893931
-
Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis.Gut. 1990 Feb;31(2):184-6. doi: 10.1136/gut.31.2.184. Gut. 1990. PMID: 2155862 Free PMC article.
-
Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.Gut. 1990 Nov;31(11):1271-6. doi: 10.1136/gut.31.11.1271. Gut. 1990. PMID: 2253912 Free PMC article. Clinical Trial.
-
5-Aminosalicylic acid in the treatment of inflammatory bowel disease.Acta Med Scand. 1987;221(3):227-42. doi: 10.1111/j.0954-6820.1987.tb00889.x. Acta Med Scand. 1987. PMID: 3296672 Review. No abstract available.
Cited by
-
The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis.Gut. 2000 Jan;46(1):64-72. doi: 10.1136/gut.46.1.64. Gut. 2000. PMID: 10601057 Free PMC article.
-
Salicylates used in inflammatory bowel disease and colchicine impair interferon-gamma induced HLA-DR expression.Gut. 1992 Jan;33(1):59-64. doi: 10.1136/gut.33.1.59. Gut. 1992. PMID: 1740279 Free PMC article.
-
Experience with the use of salazosulfapyridine for intractable diarrhea after hematopoietic stem cell transplantation.Int J Hematol. 2004 Dec;80(5):463-6. doi: 10.1532/ijh97.04089. Int J Hematol. 2004. PMID: 15646661
-
Inhibition of binding of interferon-gamma to its receptor by salicylates used in inflammatory bowel disease.Gut. 1992 Oct;33(10):1353-7. doi: 10.1136/gut.33.10.1353. Gut. 1992. PMID: 1446859 Free PMC article.
-
Drug therapy of ulcerative colitis.Br J Clin Pharmacol. 1992 Sep;34(3):189-98. doi: 10.1111/j.1365-2125.1992.tb04124.x. Br J Clin Pharmacol. 1992. PMID: 1389944 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical